Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 7, 2007 - Issue 11
Submit an article Journal homepage
632
Views
52
CrossRef citations to date
0
Altmetric
Drug Evaluations

Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy

Mazin Barry Associate Professor of Medicine, University of Ottawa, The Ottawa Hospital, Division of Infectious Diseases, Room G12-501 Smyth Road, Ottawa, K1H 8L6, ON, Canada +1 613 737 8924; +1 613 737 8164; [email protected]
, MD &
Curtis Cooper Associate Professor of Medicine, University of Ottawa, The Ottawa Hospital, Division of Infectious Diseases, Room G12-501 Smyth Road, Ottawa, K1H 8L6, ON, Canada +1 613 737 8924; +1 613 737 8164; [email protected]
, MD FRCPC
Pages 1731-1737 | Published online: 26 Oct 2007

Bibliography

  • MAYNARD JE: Hepatitis B: global importance and need for control. Vaccine (1990) 8(Suppl.):S18-S20; discussion S21-S23.
  • MAYNARD JE: Control of hepatitis B by immunization: global perspectives. Viral Hepatitis and Liver Disease. Grunne & Stratton, New York, USA (1988):967-969.
  • KIM WR: The burden of hepatitis C in the United States. Hepatology (2002) 36(5 Suppl. 1):S30-S34.
  • ALTER MJ et al.: The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA (1990) 263(9):1218-1222.
  • MCMAHON BJ et al.: Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J. Infect. Dis. (1985) 151(4):599-603.
  • BEASLEY RP: Overview on the epidemiology of hepatocellular carcinoma. In: Viral Hepatitis and Liver Disease. Hollinger FB, Lemon SB, Margolis H (Eds), Williams & Wilkins, Baltimore, USA (1991):532-535.
  • LEE WM: Hepatitis B virus infection. N. Engl. J. Med. (1997) 337(24):1733-1745.
  • HUANG K, LIN S: Nationwide vaccination: a success story in Taiwan. Vaccine (2000) 18(Suppl. 1):S35-S38.
  • ANDRE FE: Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am. J. Med. (1989) 87(3A):S14-S20.
  • MAST EE et al.: A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the advisory committee on immunization practices (ACIP) part II: immunization of adults. MMWR Recomm. Rep. (2006) 55(RR-16):1-33; quiz CE1-CE4.
  • CASSIDY WM et al.: A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: antibody responses, safety, and immunologic memory. Pediatrics (2001) 107(4):626-631.
  • CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC): Hepatitis B vaccination among high-risk adolescents and adults – San Diego, California, 1998 – 2001. MMWR Morb. Mortal. Wkly. Rep. (2002) 51(28):618-621.
  • YAMAMOTO S et al.: DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol. Immunol. (1992) 36(9):983-997.
  • SONEHARA K et al.: Hexamer palindromic oligonucleotides with 5′-CG-3′ motif(s) induce production of interferon. J. Interferon Cytokine Res. (1996) 16(10):799-803.
  • HALPERN MD, KURLANDER RJ, PISETSKY DS: Bacterial DNA induces murine interferon-g production by stimulation of interleukin-12 and TNF-α. Cell Immunol. (1996) 167(1):72-78.
  • KRIEG AM et al.: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 374(6522):546-549.
  • MARTIN-OROZCO E et al.: Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. Int. Immunol. (1999) 11(7):1111-1118.
  • SATO Y et al.: Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science (1996) 273(5273):352-354.
  • DAVIS HL et al.: CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. (1998) 160(2):870-876.
  • MARSHALL JD et al.: Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. J. Allergy Clin. Immunol. (2001) 108(2):191-197.
  • VAN NEST G et al.: An immunostimulatory oligonucleotide (ISS ODN) enhances immune responses to HBV vaccine in a variety of animal species including primates. In 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. ICAAC, San Francisco, CA, USA (1999).
  • TIGHE H et al.: Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol. (2000) 106(1 Part 1):124-134.
  • HEINEMAN TC et al.: A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine (1999) 17(22):2769-2778.
  • TRAQUINA P et al.: MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J. Infect. Dis. (1996) 174(6):1168-1175.
  • HALPERIN SA et al.: A Phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine (2003) 21(19-20):2461-2467.
  • JILG W, SCHMIDT M, DEINHARDT F: Vaccination against hepatitis B: comparison of three different vaccination schedules. J. Infect. Dis. (1989) 160(5):766-769.
  • CLEMENTS ML et al.: Effect of age on the immunogenicity of yeast recombinant hepatitis B vaccines containing surface antigen (S) or PreS2 + S antigens. J. Infect. Dis. (1994) 170(3):510-516.
  • HALPERIN SA et al.: Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine (2006) 24(1):20-26.
  • LIM SG et al.: Recominant hepatitis B surface antigen (rHBsAg) co-administered with an immunostimulatory phosphorothioate oligonucleotide (1018 ISS) proves superior protection in older subjects. In 45th Annual ICAAC. Washington, DC, USA (2005).
  • MEUER SC et al.: Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet (1989) 1(8628):15-18.
  • JUNGERS P et al.: Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine. Lancet (1994) 344(8926):856-857.
  • KOHLER H, MEUER SC: Effects of interleukin-2 on hepatitis B vaccination in uraemic patients. Lancet (1994) 344(8933):1368-1369.
  • MAURI JM, VALLES M: Effects of recombinant interleukin-2 and revaccination for hepatitis B in previously vaccinated, non-responder, chronic uraemic patients. Collaborative group of Girona. Nephrol. Dial. Transplant. (1997) 12(4):729-732.
  • CARLSSON T, STRUVE J: Granulocyte-macrophage colony-stimulating factor given as an adjuvant to persons not responding to hepatitis B vaccine. Infection (1997) 25(2):129.
  • HASAN MS et al.: Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination of healthy adults. J. Infect. Dis. (1999) 180(6):2023-2026.
  • QUIROGA JA et al.: Recombinant γ-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients. Hepatology (1990) 12(4 Part 1):661-663.
  • ERVO R et al.: Evaluation of treatments for the vaccination against hepatitis B + thymopentine. Nephron. (1992) 61(3):371-372.
  • PALESTINI M et al.: Brief treatment with thymopentin as adjuvant in vaccination for hepatitis B: controlled study in patients on periodic hemodialysis. Riv. Eur. Sci. Med. Farmacol. (1990) 12(2):135-139.
  • DUMANN H et al.: Influence of thymopentin on antibody response, and monocyte and T cell function in hemodialysis patients who fail to respond to hepatitis B vaccination. Nephron. (1990) 55(2):136-140.
  • DONATI D, GASTALDI L: Controlled trial of thymopentin in hemodialysis patients who fail to respond to hepatitis B vaccination. Nephron. (1988) 50(2):133-136.
  • ROJO JM et al.: Enhancement of lymphocyte proliferation, interleukin-2 production and NK activity by inmunoferon (AM-3), a fungal immunomodulator: variations in normal and immunosuppressed mice. Int. J. Immunopharmacol. (1986) 8(6):593-597.
  • VILLARRUBIA VG et al.: The immunosenescent phenotype in mice and humans can be defined by alterations in the natural immunity reversal by immunomodulation with oral AM3. Immunopharmacol. Immunotoxicol. (1997) 19(1):53-74.
  • SANCHEZ L et al.: AM3, an adjuvant to hepatitis B revaccination in non-responder healthy persons. J. Hepatol. (1995) 22(1):119-121.
  • PEREZ-GARCIA R et al.: AM3 (Inmunoferon) as an adjuvant to hepatitis B vaccination in hemodialysis patients. Kidney Int. (2002) 61(5):1845-1852.
  • THOELEN S et al.: Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine (1998) 16(7):708-714.
  • COOPER CL et al.: CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind Phase I/II study. J. Clin. Immunol. (2004) 24(6):693-701.
  • COOPER CL et al.: CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS (2005) 19(14):1473-1479.
  • COOPER C: CpG adjuvant + HBV vaccination in HIV infection achieves long-term seroprotection for as long as 5 years. In 14th Conference on Retroviruses and Opportunistic Infections. CROI 2007. Los Angeles, CA, USA (2007).
  • AMBROSCH F et al.: A hepatitis B vaccine formulated with a novel adjuvant system. Vaccine (2000) 18(20):2095-2101.
  • ANDRE FE, SAFARY A: Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine. Postgrad. Med. J. (1987) 63(Suppl. 2):169-177.
  • COOPER CL, MILLS E, ANGEL JB: Mitigation of antiretroviral-induced hyperlipidemia by HCV co-infection. AIDS (2006) (In Press).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.